Adalimumab: A review of side effects

Expert Opinion on Drug Safety

Volumn 4, Issue 4, 2005, Pages 637-641

  Scheinfeld, Noah ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Adalimumab; Psoriasis; Rheumatoid arthritis (RA); TNF

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ASPERGILLOSIS; BACTERIAL ARTHRITIS; BLEEDING; BLOOD CELL COUNT; BLOOD DYSCRASIA; CELLULITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOPENIA; DEMYELINATING DISEASE; DISEASE EXACERBATION; DIVERTICULITIS; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; ERYSIPELAS; ERYTHEMA; ERYTHEMA MULTIFORME; FLU LIKE SYNDROME; HISTOPLASMOSIS; HUMAN; INFECTION COMPLICATION; INJECTION PAIN; INJECTION SITE REACTION; LIVER FUNCTION TEST; LUPUS LIKE SYNDROME; LYMPHOMA; MULTIPLE SCLEROSIS; MYCOSIS; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; NOCARDIOSIS; PANCYTOPENIA; PNEUMONIA; POSTOPERATIVE INFECTION; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; PYELONEPHRITIS; RASH; REVIEW; RHEUMATOID ARTHRITIS; SINUSITIS; SKIN INFLAMMATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ARTHRITIS; DEMYELINATING DISEASES; EXANTHEMA; HEART FAILURE, CONGESTIVE; HUMANS; INFECTION; INJECTIONS, SUBCUTANEOUS; LUPUS; PSORIASIS; RISK FACTORS; SPONDYLITIS, ANKYLOSING; SYNDROME; TUBERCULOSIS;

EID: 21744457266     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.4.637     Document Type: Review

References (23)

1. SCHEINFELD N: A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J. Dermatolog. Treat. (2004) 15:280-294.
2. WASKO MC: Comorbid conditions in patients with rheumatic diseases: an update. Curr. Opin. Rheumatol. (2004) 16:109-113.
3. FLEISCHMANN R, YOCUM D: Does safety make a difference in selecting the right TNF antagonist? Arthritis. Res. Ther. (2004) 6(Suppl. 2):S12-S18.
4. EFDE MN, HOUTMAN PM, SPOORENBERG JP, JANSEN TL: Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFalpha (adalimumab) treatment. Neth. J. Med. (2005) 63:112-114.
5. MANN DL, MCMURRAY JJ, PACKER M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 109:1594-1602.
6. ANKER SD, COATS AJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. (2002) 86:123-130.
7. CHUNG ES, PACKER M, LO KH, FASANMADE AA, WILLERSON JT: Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 107:3133-3140.
8. KHANNA D, MCMAHON M, FURST DE: Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. (2004) 50:1040-1050.
9. WOLFE F, MICHAUD K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. (2004) 116:305-311.
10. DE BANDT M, SIBILIA J, LE LOET X et al.: Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res. Ther. (2005) 7:R545-R551.
11. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48:35-45. Erratum in: Arthritis Rheum. (2003) 48:855.
12. VAN DE PUTTE LBA, ATKINS C, MALAISE M et al.: Adalimumab (DE27) monotherapy in the treatment of patients with severely active rheumatoid arthritis [abstract no.467]. Arthritis Rheum. (2002) 46(9 Suppl.):S205.
13. KEYSTONE E, KAVANAUGH AF, SHARP J et al.: Adalimumab (DE27), a fully human anti-TNF-Alpha monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [abstract no. 468 plus oral proceedings]. Arthritis Rheum. (2002) 46:S205.
14. SANDBORN WJ: Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr. Gastroenterol. Rep. (2003) 5:501-505.
15. GENOVESE MC, COHEN S, MORELAND L et al.: 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. (2004) 50:1412-1419.
16. GELFAND JM, BERLIN J, VAN VOORHEES A, MARGOLIS DJ: Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch. Dermatol. (2003) 139:1425-1429.
17. EKSTROM K, HJALGRIM H, BRANDT L: Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. (2003) 48:963-970.
18. WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. (2004) 50:1740-1751.
19. ABBOTT Personal communication (2005).
20. ZIAKAS PD, GIANNOULI S, TZIOUFAS AG, VOULGARELIS M: Lymphoma development in a patient receiving anti-TNF therapy. Haematologica (2003) 88:ECR25.
21. YOUDIM A, VASILIAUSKAS EA, TARGAN SR et al.: A pilot study of adalimumab in infliximab-allergic patients. Inflamm. Bowel Dis. (2004) 10:333-338.
22. BEUTHIEN W, MELLINGHOFF HU, VON KEMPIS J: Skin reaction to adalimumab. Arthritis Rheum. (2004) 50:1690-1692.
23. DEN BROEDER AA, ASSMANN KJ, VAN RIEL PL, WETZELS JF: Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. Neth. J. Med. (2003) 61:137-141.